Angiotech CEO Hunter leaves; Bailey takes charge
This article was originally published in Scrip
Dr William Hunter has resigned his position as president and CEO of Angiotech Pharmaceuticals, a pharmaceutical and medical device company developing treatment solutions for diseases and complications associated with medical device implants, surgical interventions and acute injury. CFO Thomas Bailey will serve as interim president and CEO, while director of corporate development Tammy Neske has been promoted to chief business officer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.